FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288046623> ?p ?o ?g. }

• W4288046623 endingPage "1572" @default.
• W4288046623 startingPage "1563" @default.
• W4288046623 abstract "The combination of atezolizumab-bevacizumab has been proven to be superior to sorafenib for the treatment of unresectable hepatocellular carcinoma not amenable to locoregional treatments, becoming the standard of care of systemic therapy.This study aimed at assessing real-world feasibility of atezolizumab-bevacizumab in patients treated with tyrosine-kinase inhibitors.Among 1447 patients treated with tyrosine-kinase inhibitors from January 2010 to December 2020, we assessed the percentage of those potentially eligible to atezolizumab-bevacizumab (according to IMbrave-150 trial criteria), and the overall survival of eligible and non-eligible patients.422 (29%) patients were qualified for atezolizumab-bevacizumab therapy. The main exclusion causes were Child-Pugh class and Performance Status. Adopting the more permissive inclusion criteria of SHARP trial, 535 patients became eligible. The median overall survival of tyrosine-kinase inhibitors patients was 14.9 months, longer in eligible patients than in their counterpart due to better baseline liver function and oncological features.Real-world data indicate that less than one-third of hepatocellular carcinoma patients treated with tyrosine-kinase inhibitors are potentially eligible to atezolizumab-bevacizumab according to the registration trial criteria. These patients have a longer survival than the non-eligible ones. If the selection criteria of atezolizumab-bevacizumab trial are maintained in clinical practice, tyrosine-kinase inhibitors will remain the most used systemic therapy for hepatocellular carcinoma patients." @default.
• W4288046623 created "2022-07-27" @default.
• W4288046623 creator A5000973050 @default.
• W4288046623 creator A5001054792 @default.
• W4288046623 creator A5001098190 @default.
• W4288046623 creator A5003444448 @default.
• W4288046623 creator A5003571894 @default.
• W4288046623 creator A5013029516 @default.
• W4288046623 creator A5014172694 @default.
• W4288046623 creator A5017534922 @default.
• W4288046623 creator A5026656497 @default.
• W4288046623 creator A5029721718 @default.
• W4288046623 creator A5030619209 @default.
• W4288046623 creator A5031340334 @default.
• W4288046623 creator A5031679178 @default.
• W4288046623 creator A5032561046 @default.
• W4288046623 creator A5035805538 @default.
• W4288046623 creator A5036480997 @default.
• W4288046623 creator A5038697021 @default.
• W4288046623 creator A5039554062 @default.
• W4288046623 creator A5041639329 @default.
• W4288046623 creator A5043416750 @default.
• W4288046623 creator A5050786916 @default.
• W4288046623 creator A5061211804 @default.
• W4288046623 creator A5064787053 @default.
• W4288046623 creator A5068464587 @default.
• W4288046623 creator A5074723888 @default.
• W4288046623 creator A5079697307 @default.
• W4288046623 creator A5085511371 @default.
• W4288046623 creator A5087263289 @default.
• W4288046623 creator A5087654028 @default.
• W4288046623 creator A5087801156 @default.
• W4288046623 date "2022-11-01" @default.
• W4288046623 modified "2023-10-18" @default.
• W4288046623 title "Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors" @default.
• W4288046623 cites W1971837077 @default.
• W4288046623 cites W2024450952 @default.
• W4288046623 cites W2277004004 @default.
• W4288046623 cites W2502891277 @default.
• W4288046623 cites W2734975816 @default.
• W4288046623 cites W2787358630 @default.
• W4288046623 cites W2898314774 @default.
• W4288046623 cites W2898767814 @default.
• W4288046623 cites W3025022288 @default.
• W4288046623 cites W3138484572 @default.
• W4288046623 cites W3146059045 @default.
• W4288046623 cites W3153247821 @default.
• W4288046623 cites W3165241302 @default.
• W4288046623 cites W3183686564 @default.
• W4288046623 cites W3215759042 @default.
• W4288046623 cites W4200388794 @default.
• W4288046623 doi "https://doi.org/10.1016/j.dld.2022.07.003" @default.
• W4288046623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35906166" @default.
• W4288046623 hasPublicationYear "2022" @default.
• W4288046623 type Work @default.
• W4288046623 citedByCount "8" @default.
• W4288046623 countsByYear W42880466232022 @default.
• W4288046623 countsByYear W42880466232023 @default.
• W4288046623 crossrefType "journal-article" @default.
• W4288046623 hasAuthorship W4288046623A5000973050 @default.
• W4288046623 hasAuthorship W4288046623A5001054792 @default.
• W4288046623 hasAuthorship W4288046623A5001098190 @default.
• W4288046623 hasAuthorship W4288046623A5003444448 @default.
• W4288046623 hasAuthorship W4288046623A5003571894 @default.
• W4288046623 hasAuthorship W4288046623A5013029516 @default.
• W4288046623 hasAuthorship W4288046623A5014172694 @default.
• W4288046623 hasAuthorship W4288046623A5017534922 @default.
• W4288046623 hasAuthorship W4288046623A5026656497 @default.
• W4288046623 hasAuthorship W4288046623A5029721718 @default.
• W4288046623 hasAuthorship W4288046623A5030619209 @default.
• W4288046623 hasAuthorship W4288046623A5031340334 @default.
• W4288046623 hasAuthorship W4288046623A5031679178 @default.
• W4288046623 hasAuthorship W4288046623A5032561046 @default.
• W4288046623 hasAuthorship W4288046623A5035805538 @default.
• W4288046623 hasAuthorship W4288046623A5036480997 @default.
• W4288046623 hasAuthorship W4288046623A5038697021 @default.
• W4288046623 hasAuthorship W4288046623A5039554062 @default.
• W4288046623 hasAuthorship W4288046623A5041639329 @default.
• W4288046623 hasAuthorship W4288046623A5043416750 @default.
• W4288046623 hasAuthorship W4288046623A5050786916 @default.
• W4288046623 hasAuthorship W4288046623A5061211804 @default.
• W4288046623 hasAuthorship W4288046623A5064787053 @default.
• W4288046623 hasAuthorship W4288046623A5068464587 @default.
• W4288046623 hasAuthorship W4288046623A5074723888 @default.
• W4288046623 hasAuthorship W4288046623A5079697307 @default.
• W4288046623 hasAuthorship W4288046623A5085511371 @default.
• W4288046623 hasAuthorship W4288046623A5087263289 @default.
• W4288046623 hasAuthorship W4288046623A5087654028 @default.
• W4288046623 hasAuthorship W4288046623A5087801156 @default.
• W4288046623 hasConcept C121608353 @default.
• W4288046623 hasConcept C126322002 @default.
• W4288046623 hasConcept C143998085 @default.
• W4288046623 hasConcept C170493617 @default.
• W4288046623 hasConcept C2775949291 @default.
• W4288046623 hasConcept C2776248978 @default.
• W4288046623 hasConcept C2776694085 @default.
• W4288046623 hasConcept C2777701055 @default.
• W4288046623 hasConcept C2777802072 @default.

• next